Core Viewpoint - ST Tian Sheng Pharmaceutical Group Co., Ltd. and its controlling shareholder Liu Qun received an administrative penalty from the China Securities Regulatory Commission for financial misconduct, including inflated profits in annual reports for 2017 and 2018 [1] Financial Misconduct - In 2017, ST Tian Sheng inflated its total profit by 92,204,254.47 yuan, which accounted for 30.21% of the reported profit for that year [1] - In 2018, the inflated profit was 28,823,001.51 yuan, representing 20.61% of the reported profit for that year [1] - The company failed to timely disclose related party transactions, leading to significant omissions in the annual reports for both years [1] Penalties Imposed - The Chongqing Securities Regulatory Bureau ordered ST Tian Sheng to rectify its actions, issued a warning, and imposed a fine of 600,000 yuan [1] - Liu Qun received a warning and was fined 900,000 yuan, which included 300,000 yuan for being the directly responsible supervisor and 600,000 yuan for instructing illegal activities as the controlling shareholder [1] - Other individuals involved received varying fines and warnings, with penalties ranging from 120,000 yuan to 300,000 yuan [1] Market Bans - Liu Qun is subject to a lifetime ban from the securities market [1] - Li Hong faces an 8-year ban, while Wang Yonghong is banned for 5 years [1]

Core Viewpoint - ST Tian Sheng has been penalized by the Chongqing Securities Regulatory Bureau for financial misconduct, including inflated profits and undisclosed related party transactions in its annual reports for 2017 and 2018 [1] Group 1: Regulatory Actions - The company has been ordered to rectify its financial reporting and has received a warning along with a fine of 600,000 yuan [1] - Key personnel, including Liu Qun, have also been penalized, with Liu Qun receiving a fine of 900,000 yuan and a lifetime ban from the securities market [1] - Other individuals, Li Hong and Wang Yonghong, have been banned from the market for 8 years and 5 years respectively [1] Group 2: Company Status - Despite the penalties, the company does not face circumstances that would lead to mandatory delisting for major violations [1] - As of September 15, the company's stock has been subject to additional risk warnings, but its production and operations remain normal [1]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-066 天圣制药集团股份有限公司 关于收到中国证券监督管理委员会重庆监管局 《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）及控股股东、实际控制 人刘群先生于 2025 年 1 月 7 日收到中国证券监督管理委员会（以下简称"中国 证监会"）下发的《立案告知书》（编号：证监立案字 0152025001 号、编号： 证监立案字 0152025002 号）。因涉嫌信息披露违法违规，根据《中华人民共和 国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公 司及控股股东、实际控制人刘群先生进行立案。具体内容详见公司于 2025 年 1 月 9 日披露的《关于公司及控股股东、实际控制人收到中国证券监督管理委员 会立案告知书的公告》。 公司及相关人员于 2025 年 9 月 12 日收到中国证券监督管理委员会重庆监 管局（以下简称"重庆证监局"）出具的《行政处罚事先告知书》（处罚字 （2025）4 号），具体内容详见公司于 ...

Group 1 - The company ST Tian Sheng (SZ 002872) reported a revenue of approximately 349 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 13.31% [1] - The net loss attributable to shareholders of the listed company was approximately 45.34 million yuan [1] - The basic earnings per share showed a loss of 0.1426 yuan [1]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-065 天圣制药集团股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 （2）上述所述最高余额，是指在乙方承担担保责任的主债权确定之日，以 人民币表示的债权本金余额之和。 2、保证方式 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开 的第六届董事会第十三次会议审议通过了《关于为全资子公司提供担保的议案》。 同意公司为全资子公司湖北天圣药业有限公司（以下简称"湖北天圣"）向银行 申请授信提供担保事项，董事会授权公司经营层在担保额度范围内负责本次担保 相关的协议及文件的签署；在授信额度内，全资子公司向银行申请的具体贷款金 额以银行实际审批的最终结果为准，具体担保金额及保证期间按实际签订合同约 定 执 行 。 具 体 内 容 详 见 公 司 于 2025 年 8 月 28 日 刊 载 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的《关于为全资子公司提供担保的公告》（公告 ...

Financial Performance - Q3 2025 revenue was CNY 116,617,256.62, a decrease of 3.57% year-over-year, and a decline of 13.31% compared to the beginning of the year[5] - Net profit attributable to shareholders was CNY -8,627,087.52, a decrease of 227.69% year-over-year, and CNY -45,339,431.49 for the year-to-date, down 24.72%[5] - Basic and diluted earnings per share were both CNY -0.0271, reflecting a decrease of 227.83% year-over-year[5] - Total operating revenue for the current period was CNY 348,810,958.38, a decrease of 13.3% compared to CNY 402,356,773.40 in the previous period[32] - The net profit for the current period is -45,769,255.29, compared to -37,080,882.01 in the previous period, indicating a decline of approximately 23.0%[34] - Operating profit for the current period is -46,970,214.23, compared to -38,694,754.71 in the previous period, reflecting a decrease of about 21.5%[34] - The total comprehensive income attributable to the parent company is -45,339,431.49, compared to -36,351,799.82 in the previous period, indicating a decline of approximately 24.5%[34] - Basic and diluted earnings per share for the current period are both -0.1426, compared to -0.1143 in the previous period, reflecting a decrease of approximately 24.8%[34] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,649,005,409.57, down 3.18% from the end of the previous year[5] - Total liabilities decreased to CNY 679,171,970.60 from CNY 721,802,602.07, a reduction of 5.9%[30] - Total assets decreased to CNY 2,649,005,409.57 from CNY 2,736,124,198.16, a decline of 3.2%[30] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 2,799,122.50, down 33.89%[5] - Cash flow from operating activities netted 2,799,122.50, down from 4,233,892.91, a decrease of approximately 33.9%[37] - Cash flow from investing activities resulted in a net outflow of -10,877,335.28, compared to a net inflow of 1,965,694.10 in the previous period[37] - Cash flow from financing activities generated a net inflow of 19,883,974.42, down from 76,238,872.43, a decline of about 73.9%[37] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,340[23] - The largest shareholder, Liu Qun, holds 32.89% of the shares, with 35,000,000 shares pledged[23] Operating Costs and Expenses - Total operating costs amounted to CNY 415,765,238.26, down 10.0% from CNY 461,244,061.80 in the previous period[32] - Operating costs included CNY 180,545,140.47 in operating expenses, which decreased by 18.5% from CNY 221,601,767.96 in the previous period[32] - Research and development expenses decreased to 16,846,921.30 from 21,052,862.64, a reduction of about 20.0%[34] Other Income and Investments - Other income increased by 79.01% year-over-year, primarily due to a significant increase in VAT refunds[17] - Investment income decreased by 91.82% year-over-year, as there were no gains from the previous year's equity transfer settlement[17] Inventory and Receivables - Accounts receivable decreased to CNY 105,844,818.86 from CNY 120,099,455.35, a decline of 11.8%[28] - Inventory increased to CNY 110,440,316.57 from CNY 106,799,072.77, showing a growth of 3.1%[29] Prepayments and Borrowings - The company reported a 156.16% increase in prepayments compared to the beginning of the year, mainly due to increased advance payments for purchases[11] - Short-term borrowings rose to CNY 103,123,872.22 from CNY 80,080,055.56, an increase of 28.8%[30] Regulatory Issues - The company received an administrative penalty notice from the China Securities Regulatory Commission, indicating potential financial discrepancies in the annual report[26]

Group 1 - The company announced the resignation of non-independent director Wang Xin due to a work transfer, effective immediately upon delivery of the resignation report to the board [1][2] - Wang Xin was appointed by the shareholder Chongqing Yudian State-owned Assets Management Group Co., Ltd., and his resignation will not affect the board's operation or the company's normal production and business activities [1][2] - The company will follow legal procedures to complete the appointment of a new director as Chongqing Yudian State-owned Assets Management Group Co., Ltd. will nominate a new candidate [2] Group 2 - The board expressed gratitude for Wang Xin's contributions during his tenure [2] - As of the announcement date, Wang Xin did not hold any company shares and had no outstanding public commitments [1] - The resignation does not lead to a decrease in the number of board members below the legal minimum [1]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-063 天圣制药集团股份有限公司 同日，公司董事会收到重庆渝垫国有资产经营集团有限公司出具的函告，其 将适时提名新的董事候选人担任公司董事。届时公司将按照法定程序完成董事补 选相关工作。 王欣先生在任职期间恪尽职守、勤勉尽责，公司及董事会对王欣先生在任职 期间为公司发展做出的贡献表示衷心感谢。 特此公告。 天圣制药集团股份有限公司董事会 2025 年 10 月 23 日 关于非独立董事辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司(以下简称"公司")董事会于近日收到公司非独 立董事王欣先生的辞职报告，王欣先生为公司股东重庆渝垫国有资产经营集团有 限公司委派的董事，因其工作调动申请辞去公司第六届董事会非独立董事及董事 会各专门委员会委员职务，王欣先生原定任期至公司第六届董事会任期届满，辞 职后不再担任公司及控股子公司任何职务。 王欣先生辞职未导致公司董事会成员人数低于法定最低人数，不会影响公司 董事会的正常运作，不会影响公司正常生产经营，根据《中华人民共和国公 ...

Group 1 - The core viewpoint of the article emphasizes the increasing protection for small and medium investors by regulatory bodies, including the Supreme People's Court and the China Securities Regulatory Commission (CSRC) [1][3] - The Supreme People's Court has issued a draft interpretation regarding the Company Law, which includes provisions for the return of excessive compensation by executives in cases of financial fraud [3] - The CSRC and the Ministry of Finance have proposed a whistleblower reward system, offering 3% of the penalty amount for each case, with a maximum reward of 1 million yuan [3] Group 2 - Several listed companies, including ST Tian Sheng, Nanxin Pharmaceutical, and others, have faced regulatory penalties or investigations due to information disclosure violations [1][3] - ST Tian Sheng has been flagged for financial fraud, leading to additional risk warnings on its stock trading [4] - Nanxin Pharmaceutical's stock price dropped over 30% following the announcement of an investigation for annual report disclosure violations [5] Group 3 - KJY has been penalized for providing unauthorized guarantees amounting to 150 million yuan without proper board approval [6] - Baiyin Nonferrous Metals received a notice for significant omissions in its annual reports regarding 3 billion yuan in financial products [7] - Hainan Huatie's termination of a 3.69 billion yuan contract has raised regulatory concerns, leading to significant stock price declines [8] Group 4 - Investors affected by the aforementioned companies may be eligible for compensation if they meet specific criteria, such as purchase and sale dates of the stocks [9] - The conditions for potential claims include specific time frames for stock purchases and sales for each company involved [9] - Investors can register their losses through the "Claim Tong" public account and may need to provide documentation such as ID copies and account information [10]

Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiaries, Hubei Tian Sheng Pharmaceutical Co., Ltd. and Hunan Tian Sheng Pharmaceutical Co., Ltd., participated in the procurement of drugs including Dexamethasone in Guangdong Province, with several products proposed for selection in the upcoming procurement process [1] Group 1: Company Participation - Hubei Tian Sheng and Hunan Tian Sheng participated in the Guangdong Alliance procurement for Dexamethasone and other drugs [1] - The Guangdong Provincial Drug Trading Center published the proposed selection results for the procurement on October 10, 2025 [1] Group 2: Selected Products - Hubei Tian Sheng's products proposed for selection include: - Concentrated Sodium Chloride Injection - Clindamycin Hydrochloride Injection - Glucose Injection - Sodium Chloride Injection [1] - Hunan Tian Sheng's products proposed for selection include: - Cefoperazone Injection - Cefazolin Sodium Injection [1]